Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.80 |
| ▸ | KDR | P35968 | 8/20 | 0.80 |
| ▸ | LCK | P06239 | 5/20 | 0.80 |
| ▸ | RET | P07949 | 4/20 | 0.78 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.78 |
| ▸ | FLT1 | P17948 | 1/20 | 0.78 |
| ▸ | GAK | O14976 | 1/20 | 0.78 |
| ▸ | STK10 | O94804 | 1/20 | 0.78 |
| ▸ | FLT3 | P36888 | 1/20 | 0.78 |
| ▸ | JAK3 | P52333 | 1/20 | 0.78 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.78 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.78 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.78 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.78 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.78 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.78 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.77 |
| ▸ | CLK1 | P49759 | 1/20 | 0.77 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.70 |
| ▸ | KIF5B | P33176 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8871198 | 0.99 | EGFR (0.80) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL6675906 | 0.91 | KDR (0.73) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL5472599 | 0.89 | EGFR (1.00) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL5467825 | 0.89 | EGFR (1.00) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL5473778 | 0.89 | EGFR (0.80) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL3528866 | 0.88 | EGFR (0.67) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL5473780 | 0.87 | EGFR (0.78) | EGFRKDRLCKRETRIPK2 | |
| Whi-P131 SCHEMBL29295 | 0.87 | EGFR (1.00) | EGFRKDRLCKRETRIPK2 | |
| Hydrochloric Acid SCHEMBL5473795 | 0.87 | EGFR (0.80) | EGFRKDRLCKRETRIPK2 | |
| Whi-P131 SCHEMBL29369589 | 0.87 | EGFR (1.00) | EGFRKDRLCKRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-9353116-B2 | Methods and compositions for kinase inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353116-B2 | Methods and compositions for kinase inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353116-B2 | Methods and compositions for kinase inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-7709479-B1 | Quinazoline derivatives and their use as pharmaceuticals | ASTRAZENECA (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| CN-1391562-A | Quinazoline derivatives as medicaments | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | CN | disclosed |
| EP-1218354-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021596-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137708-A1 | METHODS AND COMPOSITIONS FOR KINASE INHIBITION | SRC, ABL1, LCK | EGFR 132/4885KDR 1851/4885LCK 3/4885 |
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | ABL1, ABL2, BCR | EGFR 196/4885KDR 1094/4885LCK 39/4885 |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | EGFR 2429/4885KDR 2584/4885LCK 1564/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | EGFR 2429/4885KDR 2584/4885LCK 1564/4885 |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885KDR 2712/4885LCK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.